<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/01/11/3216502/0/en/Teva-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference-Pivot-to-Growth-Strategy-Delivering-Growth-and-Transforming-through-Innovation.html">Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation</a>
    </div>

      <div class="me-0 me-md-5">
        Richard Francis, Teva&#39;s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva&#39;s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/01/11/3216495/0/en/Teva-and-Royalty-Pharma-Enter-Agreement-to-Accelerate-Development-of-Potential-Treatment-for-Vitiligo.html">Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo</a>
    </div>

      <div class="me-0 me-md-5">
        PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva&#39;s anti-IL-15 antibody, TEV-&#39;408. IL-15 is a key cytokine involved in multiple immune-m...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213231/0/en/Teva-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html">Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva&#39;s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/coverage/filings/2025/12/27/why-a-usd34-million-teva-stock-position-signals-confidence-in-a-long-repair-story/">Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story</a>
    </div>

      <div class="me-0 me-md-5">
        Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2025/12/24/3210318/0/en/S-P-Global-Ratings-Upgrades-Teva-to-BB-Amid-Strong-Execution-of-Pivot-to-Growth-Strategy-Moody-s-Ratings-Agency-Revises-Outlook-to-Positive.html">S&amp;P Global Ratings Upgrades Teva to ‘BB+&#39; Amid Strong Execution of Pivot to Growth Strategy; Moody&#39;s Ratings Agency Revises Outlook to Positive</a>
    </div>

      <div class="me-0 me-md-5">
        TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&amp;P Global Ratings (&quot;S&amp;P&quot;) has upgraded Teva&#39;s long-term issuer credit rating to ‘BB+&#39; from ‘BB&#39;, with a stable outlook, and that Moody&#39;s Ratings Agency (&quot;Moody&#39;s&quot;) affirmed Teva&#39;s B1a rating and revised Teva&#39;s outlook to positive from stable. These upgrades mark an...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2025/12/24/billionaire-stanley-druckenmiller-sold-nvidia-pltr/">Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street&#39;s Hottest Drug Stocks Ahead of 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street&#39;s savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund&#39;s stakes in AI darlings Nvidia and Palantir -- and profit-taking may not explain the entire story.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4855476-teva-pharmaceuticals-why-its-time-to-cash-out">Teva Pharmaceuticals: Why It&#39;s Time To Cash Out (Rating Downgrade)</a>
    </div>

      <div class="me-0 me-md-5">
        Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy. So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098/load_more?page=8">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>